# Avian Influenza > The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. Source: https://medova.health/en/knowledge/diseases/avian-influenza · Language: en ## Overview Zoonotic influenza caused by avian influenza A viruses (primarily H5N1, H7N9). High case fatality rate (~30–60% for H5N1). Acquired through direct contact with infected poultry. Pandemic potential if sustained human-to-human transmission develops. ## Medical Information - ICD-10: J09 - ICD-11: 1E31 - Causative Agent: virus - Severity: Critical - Incubation Period: 1–7 days - Mortality Rate: 60% - Vaccine available: No ## Symptoms - Cough (83%) - Fever (97%) - Shortness of breath (72%) - Chest tightness (40%) - Chills (45%) - Conjunctivitis (10%) - Diarrhea (30%) - Headache (45%) - Malaise (65%) - Myalgia (55%) - Productive cough (42%) - Sore throat (26%) - Abdominal pain (15%) - Altered consciousness (8%) - Hemoptysis (10%) - Loss of appetite (35%) - Nausea (18%) - Tachycardia (40%) - Vomiting (20%) - Rhinorrhea (15%) ## Transmission - Zoonotic contact (Primary route) - Airborne transmission - Contaminated Food - Fomites (contaminated surfaces) - Respiratory droplets ## Overview Avian influenza (commonly called "bird flu") refers to disease caused by infection with **influenza type A viruses** that are adapted to birds but can occasionally infect humans and other mammals. Multiple subtypes have caused zoonotic infections in humans, most notably **H5N1**, **H7N9**, **H5N6**, and **H9N2**, each with distinct epidemiological profiles and clinical severity. Avian influenza viruses circulate widely among wild aquatic birds (the natural reservoir) and can spread to domestic poultry, where highly pathogenic strains cause devastating outbreaks. Human infections occur sporadically through **direct or close contact with infected poultry or contaminated environments**, particularly in live poultry markets. There is currently **no sustained human-to-human transmission**, but limited person-to-person spread has been documented in rare clusters. Since the first recognized human cases of H5N1 in **Hong Kong in 1997**, the WHO has documented **over 880 confirmed H5N1 cases with more than 460 deaths** (case fatality rate ~53%). H7N9, first identified in China in 2013, has caused approximately **1,500 confirmed cases with a CFR of ~40%**. Avian influenza viruses are of critical concern to global public health because of their **pandemic potential** — the possibility that a highly pathogenic avian virus could acquire the ability to spread efficiently between humans, potentially causing a devastating pandemic. ## Overview Avian influenza encompasses a group of influenza A viruses with zoonotic potential, characterized by their hemagglutinin (H) and neuraminidase (N) surface proteins. **Key facts:** - **Causative agents:** Influenza A viruses — 18 hemagglutinin (H1–H18) and 11 neuraminidase (N1–N11) subtypes; subtypes with documented human infections include H5N1, H7N9, H5N6, H9N2, H7N7, H7N2, H7N3, H10N8, and H6N1 - **Natural reservoir:** Wild aquatic birds (waterfowl, shorebirds) carry low-pathogenic avian influenza (LPAI) asymptomatically - **Pathogenicity classification:** - **Highly Pathogenic Avian Influenza (HPAI):** Causes severe systemic disease in poultry with >75% mortality; primarily H5 and H7 subtypes - **Low Pathogenic Avian Influenza (LPAI):** Causes mild or no disease in poultry; can mutate to HPAI - **Incubation period:** H5N1: typically 2–8 days (up to 17 days); H7N9: 1–10 days - **Transmission to humans:** Direct contact with infected poultry (live or dead), contaminated environments (live bird markets, poultry farms), or rarely through contaminated water; no evidence of transmission through properly cooked poultry or eggs **Major zoonotic subtypes:** | Subtype | First human case | Total human cases | CFR | Geographic focus | |---------|-----------------|-------------------|-----|-----------------| | H5N1 | 1997 (Hong Kong) | >880 | ~53% | Egypt, Indonesia, Vietnam, Cambodia | | H7N9 | 2013 (China) | ~1,500 | ~40% | China | | H5N6 | 2014 (China) | ~80+ | ~30–40% | China | | H9N2 | 1998 | ~100+ | <5% | China, Egypt, Bangladesh | Avian influenza is classified as a **WHO-monitored disease** with pandemic preparedness implications under the International Health Regulations (IHR 2005). ## Emergency Signs **Seek emergency medical attention immediately** if you develop the following symptoms within 10 days of contact with poultry or birds in an area with known avian influenza outbreaks: **Critical warning signs:** - **High fever (>38°C) with cough and progressive dyspnea** — especially if worsening over 24–48 hours; lower respiratory involvement in avian influenza progresses rapidly - **Difficulty breathing or shortness of breath** at rest — suggests developing ARDS; this can deteriorate within hours - **Cyanosis** — bluish discoloration of lips, fingertips, or skin indicating hypoxemia - **Chest pain** — pleuritic or persistent, suggesting pneumonia or myocarditis - **Altered mental status** — confusion, drowsiness, or disorientation may indicate encephalitis or severe hypoxemia - **Persistent vomiting and inability to maintain hydration** - **Bloody or purulent sputum** **When to suspect avian influenza specifically:** - Onset of **severe respiratory illness** within 2–10 days of: - Visiting a **live poultry market** in an affected region - Direct contact with **sick or dead poultry** or wild birds - Working on or visiting a **poultry farm** during an outbreak - Contact with a **confirmed avian influenza patient** (rare but important) - **Occupational exposure** — poultry workers, veterinarians, cullers involved in outbreak response **Critical actions:** 1. **Inform healthcare providers immediately** about poultry/bird exposure history — this is essential for triggering appropriate testing and infection control 2. **Isolation** — avian influenza patients must be placed in **airborne infection isolation** (negative pressure room) pending confirmation 3. **Oseltamivir should be started empirically** — do not wait for laboratory confirmation; early treatment (within 48 hours of symptom onset) significantly improves survival 4. **Public health notification** — all suspected cases must be reported to national health authorities under IHR 2005 ## Detailed Symptoms The clinical spectrum of avian influenza in humans ranges from asymptomatic infection and mild conjunctivitis to fulminant viral pneumonia and death. Severity depends heavily on the infecting subtype. **H5N1 (most severe):** - **Onset:** Abrupt, with high fever (>38°C), severe myalgia, headache, and malaise - **Lower respiratory tract involvement** occurs early — productive cough, dyspnea, and pleuritic chest pain develop within 1–5 days of symptom onset - **Rapid progression** to bilateral pneumonia, often with diffuse ground-glass infiltrates on chest imaging - **Acute respiratory distress syndrome (ARDS)** develops in the majority of hospitalized patients, typically by days 3–7 - **Gastrointestinal symptoms** are common — watery diarrhea, vomiting, and abdominal pain may precede respiratory symptoms in up to 70% of cases - **Multi-organ dysfunction** — renal failure, hepatic impairment, and cardiac dysfunction - **Encephalitis** — rare but reported in children - **Lymphopenia** is a hallmark laboratory finding and predictor of severity - Median time from symptom onset to death: **9–10 days** in fatal cases **H7N9:** - Similar presentation to severe seasonal influenza initially — fever, cough, dyspnea - **Rapid progression to pneumonia and ARDS** in most hospitalized cases - **Older patients** (median age 58 years) and those with comorbidities are disproportionately affected - Less gastrointestinal involvement compared to H5N1 **H9N2 and other low-pathogenicity subtypes:** - Typically cause **mild upper respiratory illness** — fever, cough, sore throat - **Conjunctivitis** — particularly reported with H7 subtypes (e.g., H7N7 outbreak in the Netherlands, 2003) - Most cases are self-limited **Notable features distinguishing avian influenza from seasonal influenza:** - **More prominent lower respiratory tract involvement** from onset - **Diarrhea** as an early symptom (uncommon in seasonal influenza) - **Rapid clinical deterioration** despite antiviral therapy - **Lymphopenia** (rather than leukocytosis) ## Course of Disease The clinical course of avian influenza in humans, particularly H5N1 and H7N9, typically follows a rapid and aggressive trajectory distinct from seasonal influenza. **Exposure and incubation:** - Virus exposure through inhalation of aerosolized virus particles, direct contact with infected poultry or contaminated surfaces, or possibly ingestion - **Incubation period:** H5N1: 2–8 days (up to 17 days reported); H7N9: 1–10 days (median 5 days) - During incubation, the virus replicates primarily in the respiratory epithelium **Days 1–3 (symptom onset):** - Abrupt onset of **high fever** (often >39°C), myalgia, headache, and malaise - Cough is initially non-productive - **Gastrointestinal symptoms** (diarrhea, vomiting, abdominal pain) develop early in ~70% of H5N1 cases — a distinguishing feature from seasonal influenza - Upper respiratory symptoms (rhinorrhea, sore throat) are less prominent than in seasonal influenza **Days 3–7 (rapid progression):** - Progressive dyspnea develops as viral pneumonia establishes in the lower respiratory tract - Chest imaging shows bilateral pulmonary infiltrates with rapid progression - **ARDS** develops in the majority of hospitalized H5N1/H7N9 cases, typically between days 3–7 - Lymphopenia deepens; inflammatory markers (CRP, ferritin, LDH) rise sharply - **Cytokine storm** — excessive immune activation with elevated IL-6, TNF-alpha, and IP-10; a major driver of lung injury and multi-organ dysfunction **Days 7–14 (critical phase):** - Patients requiring mechanical ventilation face the highest mortality risk during this window - **Multi-organ dysfunction** may develop: acute kidney injury, hepatic impairment, rhabdomyolysis, disseminated intravascular coagulation (DIC) - **Secondary bacterial pneumonia** may complicate the course - **Cardiac involvement** — myocarditis, pericarditis reported in some cases **Outcome:** - **Fatal cases:** Median time from onset to death is **9–10 days** for H5N1 (range 4–30 days); death typically results from refractory hypoxemia, multi-organ failure, or septic shock from secondary infection - **Survivors:** Recovery from ARDS is prolonged; median ICU stay 2–3 weeks; full pulmonary recovery may take months - **Mild cases (H9N2, some H7N9):** Self-limited illness resolving in 5–7 days without hospitalization ## Diagnosis Diagnosis of avian influenza requires a high index of clinical suspicion based on exposure history, combined with specialized laboratory testing. Standard rapid influenza tests are **insufficient** for ruling out avian influenza. **Case definition (WHO):** A person with acute respiratory illness (fever ≥38°C and cough) with onset within 10 days of: - Direct contact with infected or suspected infected poultry (live or dead) or their environments - Close contact with a confirmed or probable avian influenza case - Working in a laboratory handling avian influenza specimens - Living in or traveling to an area with active avian influenza outbreaks in poultry or humans **Laboratory diagnosis:** - **RT-PCR (reverse transcription polymerase chain reaction)** — the **gold standard** for confirmation - Subtype-specific primers identify H5, H7, H9, and neuraminidase subtypes - Specimens: nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage (BAL), tracheal aspirate - **Lower respiratory tract specimens** (BAL, tracheal aspirate) have higher sensitivity than upper respiratory specimens for H5N1 - Results typically available within 4–6 hours at reference laboratories - **Virus culture** — provides definitive identification and allows antigenic characterization; **must be performed in BSL-3 or higher containment** facilities; takes 2–7 days - **Rapid influenza diagnostic tests (RIDTs):** May detect influenza A but **cannot differentiate subtypes** and have **poor sensitivity** (~30–50%) for avian influenza; a negative RIDT does NOT rule out avian influenza - **Immunofluorescence assay (DFA/IFA):** Can detect influenza A but cannot distinguish avian subtypes; moderate sensitivity - **Serology:** Microneutralization assay and hemagglutination inhibition (HI) using avian influenza antigens; requires paired sera (acute + convalescent, 14–21 days apart); useful for retrospective diagnosis and seroprevalence studies; **must be performed in BSL-3** **Imaging:** - **Chest X-ray:** Bilateral diffuse infiltrates, ground-glass opacities, consolidation — often multilobar from early in the course - **CT chest:** Bilateral ground-glass opacities with or without consolidation; rapid progression is characteristic **Important notes:** - All specimens from suspected avian influenza cases must be handled with **enhanced biosafety precautions** (BSL-3 for culture) - **WHO reference laboratories** should be notified for novel subtype confirmation - Testing should be coordinated with national influenza centers or WHO Collaborating Centres ## Treatment Treatment of avian influenza in humans centers on **early antiviral therapy** and **aggressive supportive care**, particularly respiratory support. **Antiviral therapy:** - **Oseltamivir (Tamiflu)** — neuraminidase inhibitor; WHO-recommended first-line treatment - Adult dose: **75 mg twice daily** for a minimum of **5 days** (extended courses of 10 days or longer are often used for severe disease) - **Must be started as early as possible** — ideally within 48 hours of symptom onset; associated with significantly reduced mortality when administered early - Should be initiated **empirically** in any suspected case — do not wait for laboratory confirmation - Higher doses (150 mg twice daily) have been used in severe cases, though evidence for improved efficacy is limited - **Zanamivir** — inhaled neuraminidase inhibitor; alternative to oseltamivir; IV formulation available for critically ill patients unable to take oral medication - **Peramivir** — IV neuraminidase inhibitor; useful when oral and inhaled routes are not feasible - **Baloxavir marboxil** — cap-dependent endonuclease inhibitor; active against avian influenza viruses in vitro; may be used in combination with oseltamivir for severe cases (WHO conditional recommendation) - **Resistance:** Most H5N1 and H7N9 strains remain susceptible to neuraminidase inhibitors, but oseltamivir resistance (H275Y mutation) has been documented; zanamivir generally retains activity against oseltamivir-resistant strains **Supportive care:** - **Oxygen therapy** — early and aggressive supplemental oxygen; target SpO₂ >92% - **Mechanical ventilation** — required in the majority of severe H5N1 and H7N9 cases; lung-protective ventilation strategies (low tidal volume, PEEP) per ARDS guidelines - **Prone positioning** — improves oxygenation in ARDS - **ECMO (extracorporeal membrane oxygenation)** — considered for refractory hypoxemia; limited availability - **Fluid management** — conservative fluid strategy to avoid pulmonary edema - **Corticosteroids** — not routinely recommended; may worsen viral replication; used only for refractory shock or specific indications - **Antibiotic therapy** for secondary bacterial pneumonia, which is common in severe cases **Investigational therapies:** - Convalescent plasma and hyperimmune globulin have shown mixed results - Monoclonal antibodies targeting the hemagglutinin stalk are in clinical development ## Prevention Details Prevention of human avian influenza focuses on **reducing exposure to infected poultry**, **poultry industry biosecurity**, and **pandemic preparedness**. No widely available vaccine exists for avian influenza subtypes, though candidate vaccines have been developed and stockpiled. **Personal protective measures for travelers and the public:** - **Avoid live poultry markets** (wet markets) in countries with reported avian influenza outbreaks — this is the most effective individual measure; live bird markets are the primary interface for zoonotic transmission - **Avoid contact with sick or dead poultry** and wild birds — do not handle or approach birds that appear ill, dying, or recently dead - **Do not visit poultry farms** during outbreaks unless essential and with appropriate personal protective equipment (PPE) - **Practice hand hygiene** — wash hands thoroughly with soap and water after any contact with birds, poultry environments, or raw poultry products - **Food safety:** Poultry meat and eggs are safe to eat when **thoroughly cooked** (internal temperature >70°C/158°F); avian influenza viruses are killed by heat; avoid raw or undercooked poultry and eggs in affected areas - Seasonal influenza vaccination does **not** protect against avian influenza but is recommended to reduce the risk of co-infection and potential reassortment **Occupational protection (poultry workers, cullers, veterinarians):** - **Full PPE** during contact with potentially infected poultry: N95/FFP2 respirator, goggles or face shield, disposable gown, gloves, boots - **Seasonal influenza vaccination** — recommended to reduce reassortment risk - **Antiviral prophylaxis** — oseltamivir 75 mg daily may be offered during high-risk exposure activities **Poultry industry biosecurity (public health level):** - Rapid detection and reporting of HPAI outbreaks in poultry - Stamping out (culling) of infected flocks — the primary control measure - Poultry vaccination (H5, H7) — used in some countries (China, Egypt, Indonesia) to reduce viral circulation in poultry - Separation of domestic poultry from wild birds; biosecurity standards on commercial farms - Closure of live bird markets during outbreaks **Pandemic preparedness:** - WHO coordinates a global pandemic influenza preparedness framework (PIP Framework) - **Pre-pandemic H5N1 vaccines** have been developed and are stockpiled by several countries and WHO - Pandemic vaccine production capacity: estimated **4.2 billion doses** within 6 months of pandemic declaration using mRNA, cell-based, and egg-based platforms - **Surveillance** of avian influenza viruses in animals and humans is critical for early detection of mutations enhancing human transmissibility ## Travel Advice **Risk assessment for travelers:** The risk of avian influenza for most travelers is **very low**. Human infections are sporadic and almost exclusively linked to direct contact with infected poultry or contaminated environments. Standard tourist activities, including consuming properly cooked poultry, pose negligible risk. **Situations that increase risk:** - **Visiting live poultry markets** (wet markets) in countries with active HPAI outbreaks — the single most important risk factor for travelers - **Visiting or working on poultry farms** during outbreaks - **Handling sick or dead birds** (domestic or wild) - **Rural travel** in areas with ongoing poultry outbreaks where backyard poultry keeping is common **Regions with historical or ongoing avian influenza activity in poultry and/or humans:** - **H5N1:** Egypt, Indonesia, Vietnam, Cambodia, China, Bangladesh, Myanmar, parts of West Africa (Nigeria), and increasingly global HPAI outbreaks in poultry/wild birds (2021–present: Europe, Americas, Africa) - **H7N9:** China (primarily eastern provinces; no human cases since 2019 following mass poultry vaccination) - **H5N6:** China (sporadic human cases) - **H5N1 clade 2.3.4.4b (2021–present):** Unprecedented global spread in wild birds and poultry across Europe, Americas, Africa, and Asia; sporadic human cases including in previously unaffected countries **Traveler precautions:** - **Avoid live poultry markets** — do not enter areas where live birds are sold, slaughtered, or de-feathered - Do not touch or feed poultry, pigeons, or wild birds - **Eat only thoroughly cooked poultry and eggs** — properly cooked food is safe - **Wash hands frequently** — especially before eating and after visiting markets or rural areas - **Carry alcohol-based hand sanitizer** - Report any illness with fever and respiratory symptoms developing within 10 days of poultry exposure to a healthcare provider, and disclose your travel and exposure history **Post-travel:** - If you develop **fever with respiratory symptoms** within 10 days of contact with poultry or live bird markets, seek medical attention immediately and inform the clinician of your exposure history - The WHO does **not** recommend travel restrictions to countries with avian influenza outbreaks in poultry ## How common is it? Avian influenza has a complex epidemiology spanning animal and human health, with sporadic zoonotic infections occurring against a background of massive global poultry and wild bird outbreaks. **H5N1 (since 1997):** - First human cases: **Hong Kong, 1997** (18 cases, 6 deaths); re-emerged in 2003 in Southeast Asia - Cumulative total (WHO, 2024): **>880 confirmed human cases** in 23 countries, with **>460 deaths** (CFR ~53%) - **Countries with most human cases:** Egypt (~360 cases), Indonesia (~200 cases), Vietnam (~130 cases), Cambodia (~60 cases), China (~50 cases) - Since 2020: H5N1 clade 2.3.4.4b has caused **unprecedented panzootic** in wild birds and poultry across all continents except Oceania; massive die-offs in seabirds, marine mammals; sporadic human cases in poultry workers and dairy farm workers (USA, 2024) **H7N9 (since 2013):** - First identified: **Eastern China, March 2013** - Five epidemic waves (2013–2017), with the fifth wave being the largest - Cumulative total: **~1,568 confirmed human cases**, ~616 deaths (CFR ~39%) - Virtually all cases from **China** (>99%); rare exported cases in travelers - **Near-zero human cases since 2019** following implementation of mass H7N9 vaccination in Chinese poultry **Other subtypes:** - **H5N6:** ~80+ human cases (2014–present), primarily China; CFR ~30–40% - **H9N2:** ~100+ human cases; predominantly mild; widespread in poultry across Asia, Middle East, Africa; significant because it contributes internal gene segments to other avian influenza reassortants - **H7N7:** Netherlands, 2003 — 89 human cases (1 death); mostly conjunctivitis - **H10N8, H6N1:** Isolated human cases in China **Current global situation (2024–2026):** - **H5N1 clade 2.3.4.4b panzootic** continues with unprecedented geographic spread - New host species affected: dairy cattle (USA, 2024), foxes, seals, sea lions - Enhanced surveillance globally; WHO maintains risk assessment as **"low" for general population** but "low-to-moderate" for occupationally exposed individuals - Pandemic preparedness planning intensified; mRNA and cell-based vaccine candidates targeting clade 2.3.4.4b are in clinical trials **Pandemic risk assessment:** - Current avian influenza viruses **lack efficient human-to-human transmissibility** - Key mutations in the hemagglutinin receptor binding site (e.g., PB2 E627K, HA Q226L) that could increase mammalian adaptation are under continuous monitoring - The 1918, 1957, and 1968 influenza pandemics all involved avian-origin gene segments ## Risk Factors Risk factors for avian influenza in humans relate primarily to exposure intensity and host susceptibility. **Exposure-related risk factors (most important):** - **Direct contact with infected poultry** — handling, slaughtering, de-feathering, or butchering infected birds is the highest-risk activity; studies show a dose-response relationship between exposure intensity and infection risk - **Visiting live bird/poultry markets** — the primary site of zoonotic transmission in Asia; environmental contamination with virus is common on surfaces, in water, and in air - **Poultry farm workers** — commercial and backyard poultry farmers in outbreak areas - **Cullers and outbreak responders** — personnel involved in poultry depopulation (stamping out) during HPAI outbreaks - **Backyard poultry keeping** — common in rural Asia, Africa, and the Middle East; close human-bird contact with minimal biosecurity - **Veterinarians and laboratory workers** handling avian influenza specimens - **Household contact with infected poultry** — keeping poultry in or near living quarters **Host risk factors for severe disease:** - **Age distribution:** - H5N1: Median age of cases is ~20–30 years; children and young adults are disproportionately affected; CFR highest in ages 10–39 - H7N9: Median age ~58 years; older adults with comorbidities are most affected - **Underlying medical conditions** — chronic pulmonary disease, cardiovascular disease, diabetes mellitus, obesity, and chronic kidney disease increase severity - **Immunosuppression** — HIV/AIDS, organ transplant recipients, and patients on immunosuppressive therapy - **Pregnancy** — associated with increased severity (as with seasonal and pandemic influenza) - **Delayed antiviral treatment** — the most important modifiable risk factor for poor outcome; treatment >48 hours after onset significantly increases mortality - **Male sex** — slight male predominance in H7N9 cases, possibly reflecting occupational exposure patterns **Environmental and behavioral factors:** - **Live poultry market frequency** — markets that hold birds overnight and have poor sanitation have higher environmental contamination - **Rural versus urban** — backyard poultry keeping in rural areas creates sustained close contact - **Season** — H7N9 cases peak in winter/spring in China, coinciding with increased live poultry trade and influenza seasonality ## Complications Details Avian influenza, particularly H5N1 and H7N9, can produce severe and rapidly progressive complications that distinguish it from seasonal influenza. **Pulmonary complications (most prominent):** - **Viral pneumonia** — bilateral, rapidly progressive; the primary manifestation of severe disease; develops within 3–7 days of symptom onset; chest imaging shows multilobar consolidation and ground-glass opacities - **Acute Respiratory Distress Syndrome (ARDS)** — develops in **>60%** of hospitalized H5N1 patients and ~50% of hospitalized H7N9 patients; median onset day 3–7; associated with very high mortality (>60% once mechanical ventilation is required) - **Pneumothorax and pneumomediastinum** — may complicate mechanical ventilation in ARDS patients - **Secondary bacterial pneumonia** — *Staphylococcus aureus*, *Streptococcus pneumoniae*, and gram-negative bacteria are common superinfecting pathogens; contributes to late mortality - **Pulmonary fibrosis** — may develop as a long-term sequela of ARDS; can cause permanent reduction in lung function in survivors **Extrapulmonary complications:** - **Cytokine storm (hyperinflammatory response)** — a hallmark of severe H5N1 infection; markedly elevated IL-6, IL-8, IL-10, TNF-alpha, IP-10, MCP-1, and MIG in serum; drives multi-organ injury; similar mechanism to severe COVID-19 and sepsis - **Acute kidney injury** — develops in 25–40% of critically ill patients; multifactorial (hypotension, cytokine-mediated injury, rhabdomyolysis) - **Hepatic dysfunction** — elevated transaminases are common; fulminant hepatic failure is rare but reported - **Rhabdomyolysis** — myoglobinuria contributing to renal injury - **Disseminated intravascular coagulation (DIC)** — coagulopathy with prolonged PT/INR, thrombocytopenia, and elevated D-dimer - **Cardiac complications** — myocarditis, pericarditis, and electrocardiographic abnormalities; cardiac dysfunction contributes to hemodynamic instability - **Encephalitis/encephalopathy** — reported primarily in children with H5N1; seizures, altered consciousness; the virus has been detected in brain tissue at autopsy **Hematologic complications:** - **Lymphopenia** — reduction in CD4+ and CD8+ T cells; a hallmark of severe disease and an independent predictor of mortality - **Hemophagocytic lymphohistiocytosis (HLH)** — reactive hemophagocytic syndrome has been documented in fatal H5N1 cases; characterized by cytopenias, hyperferritinemia, and activated macrophages engulfing blood cells **Long-term sequelae in survivors:** - Prolonged **pulmonary impairment** and reduced exercise capacity - **Post-ICU syndrome** — physical, cognitive, and psychological effects of prolonged critical illness - **Neuropsychiatric sequelae** in rare cases of CNS involvement ## Recovery & Outlook The prognosis of avian influenza in humans varies dramatically by subtype, ranging from nearly universal recovery (H9N2) to majority fatality (H5N1). **Case fatality rates by subtype:** - **H5N1:** ~53% overall CFR among confirmed cases (>460 deaths out of >880 cases); likely overestimated due to surveillance bias (mild cases are underdiagnosed) - **H7N9:** ~40% overall CFR among hospitalized cases; ~1.4% estimated when including seropositive (mild/asymptomatic) cases from serosurveys - **H5N6:** ~30–40% among reported cases - **H9N2:** <5% CFR; most infections are mild **Prognostic factors for poor outcome in H5N1/H7N9:** - **Delay in antiviral treatment** — the most modifiable risk factor; starting oseltamivir >48 hours after symptom onset is associated with significantly higher mortality - **Age:** Children >5 years and young adults have historically been most affected by H5N1 (unusual age distribution); for H7N9, older adults (>60) have the worst outcomes - **Comorbidities** — chronic lung disease, cardiovascular disease, diabetes, obesity, and immunosuppression worsen prognosis - **Lymphopenia** at presentation — a strong independent predictor of mortality - **Progression to ARDS** — once mechanical ventilation is required, mortality exceeds 60–70% - **Multi-organ dysfunction** — renal failure, hepatic dysfunction, and coagulopathy indicate poor prognosis - **Viral load** — higher initial viral RNA levels in blood and respiratory specimens correlate with mortality **Recovery:** - Survivors of severe disease often experience prolonged **ICU stays** (median 2–3 weeks) and require extended rehabilitation - **Pulmonary fibrosis** may develop as a sequela of ARDS - **Neuropsychiatric sequelae** have been reported after H5N1 encephalitis - Patients with mild avian influenza infections (typically H9N2) recover fully within 1–2 weeks ## Sources & content verification - Data sources: SafeTripVax Medical Team (WHO Avian Influenza Data 2024, CDC, ECDC), WHO Disease Factsheets 2024 + CDC Yellow Book 2024 + Heymann CDD 21st ed. - Generated by: AI + Human review - Review status: Awaiting medical review - Last updated: 2026-03-29 - [www.who.int](https://www.who.int/news-room/fact-sheets) --- The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. [Full terms of use](https://medova.health/en/terms)